Jim Simons Vaxart, Inc. Transaction History

Renaissance Technologies LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$0.53 - $1.3 $40,634 - $99,669	-76,669 Reduced 8.29%	847,631 $567,000
Q1 2024 May 13, 2024	BUY	$0.56 - $1.41 $493,808 - $1.24 Million	881,800 Added 2074.82%	924,300 $1.2 Million
Q4 2023 Feb 13, 2024	BUY	$0.57 - $0.85 $4,446 - $6,630	7,800 Added 22.48%	42,500 $24,000
Q3 2023 Nov 14, 2023	SELL	$0.69 - $0.85 $522,540 - $643,709	-757,305 Reduced 95.62%	34,700 $26,000
Q2 2023 Aug 11, 2023	BUY	$0.6 - $1.41 $441,328 - $1.04 Million	735,548 Added 1302.85%	792,005 $578,000
Q1 2023 May 12, 2023	SELL	$0.71 - $1.25 $678,304 - $1.19 Million	-955,359 Reduced 94.42%	56,457 $43,000
Q4 2022 Feb 13, 2023	BUY	$0.75 - $2.24 $758,862 - $2.27 Million	1,011,816 New	1,011,816 $972,000
Q3 2020 Nov 13, 2020	SELL	$4.78 - $16.97 $2.95 Million - $10.5 Million	-616,328 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$1.68 - $8.85 $2.62 Million - $13.8 Million	-1,557,400 Reduced 71.65%	616,328 $5.46 Million
Q1 2020 May 14, 2020	BUY	$0.34 - $2.87 $273,344 - $2.31 Million	803,954 Added 58.69%	2,173,728 $3.85 Million
Q4 2019 Feb 13, 2020	BUY	$0.28 - $0.39 $113,069 - $157,490	403,821 Added 41.81%	1,369,774 $480,000
Q3 2019 Nov 13, 2019	BUY	$0.3 - $0.75 $67,890 - $169,725	226,300 Added 30.6%	965,953 $347,000
Q2 2019 Aug 12, 2019	BUY	$0.63 - $2.04 $255,076 - $825,961	404,883 Added 120.94%	739,653 $496,000
Q1 2019 May 14, 2019	BUY	$1.5 - $2.34 $95,412 - $148,842	63,608 Added 23.46%	334,770 $649,000
Q4 2018 Feb 13, 2019	BUY	$1.88 - $5.25 $509,784 - $1.42 Million	271,162 New	271,162 $510,000

109

39.7M

96.7K

226K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $89.8M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.